Abstract
The development of anti-vascular endothelial growth factor (VEGF) therapy is both revolutionary and unprecedented in the history of ophthalmology. In the past ophthalmic drugs have been the reformulations of previously well characterized systemic drugs. Anti-VEGF therapies for retinal diseases represent the first time that systemic and ocular complications are being initially defined by the ophthalmic profession. The purpose of this chapter is to review both the described and potential complications of Anti-VEGF therapies. This chapter will describe obvious associated complications such as endophthalmitis and elevated intraocular pressure and non obvious complications such as exacerbation of hypertension, increased risk of thromboembolic events, renal thrombosis and issues with surgical wound healing.
Keywords: Age-related macular degeneration, intravitreal injections, vascular endothelial growth factor, VEGF, treatment, physiology, Endophthalmitis, Ganglion Cell Changes, Geographic Atrophy, Vitreous Hemorrhage
Current Drug Therapy
Title:Complications of Anti-Vascular Endothelial Growth Factor Drugs
Volume: 7 Issue: 2
Author(s): Michael Tolentino
Affiliation:
Keywords: Age-related macular degeneration, intravitreal injections, vascular endothelial growth factor, VEGF, treatment, physiology, Endophthalmitis, Ganglion Cell Changes, Geographic Atrophy, Vitreous Hemorrhage
Abstract: The development of anti-vascular endothelial growth factor (VEGF) therapy is both revolutionary and unprecedented in the history of ophthalmology. In the past ophthalmic drugs have been the reformulations of previously well characterized systemic drugs. Anti-VEGF therapies for retinal diseases represent the first time that systemic and ocular complications are being initially defined by the ophthalmic profession. The purpose of this chapter is to review both the described and potential complications of Anti-VEGF therapies. This chapter will describe obvious associated complications such as endophthalmitis and elevated intraocular pressure and non obvious complications such as exacerbation of hypertension, increased risk of thromboembolic events, renal thrombosis and issues with surgical wound healing.
Export Options
About this article
Cite this article as:
Tolentino Michael, Complications of Anti-Vascular Endothelial Growth Factor Drugs, Current Drug Therapy 2012; 7 (2) . https://dx.doi.org/10.2174/157488512800675959
DOI https://dx.doi.org/10.2174/157488512800675959 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Heme Oxygenase-1: A Potential Antihypertensive Target?
Current Hypertension Reviews Plasma Acetylcholinesterase Activity Correlates with Intracerebral β-Amyloid Load
Current Alzheimer Research Lipid based Nanocarriers for Oral Delivery of Cancer Chemotherapeutics: An Insight in the Intestinal Lymphatic Transport
Drug Delivery Letters Successful Applications of Computer Aided Drug Discovery: Moving Drugs from Concept to the Clinic
Current Topics in Medicinal Chemistry Hematologic Abnormalities in the Antiphospholipid Syndrome
Current Rheumatology Reviews Preface [Hot topic: Modern Aspects in the Design And Discovery of Novel Antihypertensive Drugs (Guest Editor: Thomas Mavromoustakos)]
Current Topics in Medicinal Chemistry Combined Dyslipidemia: Should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia?
Current Pharmaceutical Design Statins in Peripheral Arterial Disease
Current Pharmaceutical Design PET Imaging and Coronary Circulatory Function: Non-Invasive Mechanistic Insights and Cardiovascular Prognosis
Current Cardiology Reviews Tissue Factor and Hypertension
Current Hypertension Reviews Soybean and Processed Soy Foods Ingredients, and Their Role in Cardiometabolic Risk Prevention
Recent Patents on Food, Nutrition & Agriculture The Potential Role of Thiamine (Vitamin B1) in Diabetic Complications
Current Diabetes Reviews Late versus Early Onset Depression in Elderly Patients: Vascular Risk and Cognitive Impairment
Current Aging Science Preclinical and Clinical Studies of Novel Breast Cancer Drugs Targeting Molecules Involved in Protein Kinase C Signaling, the Putative Metastasis-Suppressor Gene Cap43 and the Y-box Binding Protein-1
Current Medicinal Chemistry Dietary Prevention of Coronary Heart Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Common Variants for Heart Failure
Current Genomics Electrocardiographic Abnormalities in Thalassemia Patients with Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Phylogenetic Aspects of Nucleobindin-2/Nesfatin-1
Current Pharmaceutical Design Pleiotropic Effects of ARB on Dyslipidemia
Current Vascular Pharmacology Role of Nitrosative Stress and Activation of Poly(ADP-ribose) Polymerase-1 in Cardiovascular Failure Associated with Septic and Hemorrhagic Shock
Current Vascular Pharmacology